Novo ends inhaled-insulin development

01/14/2008 | Bloomberg

Novo Nordisk A/S has ended development of AERx, its investigational insulin inhaler. "We have realized that the trend is for physicians to start treatment with something simple rather than a device that has to be loaded with insulin for each mealtime use," Novo chief scientific officer Mads Krogsgaard Thomsen said in a telephone interview.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN